1. Low Plasma 25-Hydoxyvitamin D at Diagnosis Predicts Poor Outcomes in Patients with Bladder Cancer: A Prospective Cohort Study
- Author
-
Mohamed Kacem Ben Fradj, Mohamed Bassem Hammami, Yassine Nouira, Moncef Feki, Mokhtar Bibi, and Amani Kallel
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,MEDLINE ,Medicine (miscellaneous) ,urologic and male genital diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,polycyclic compounds ,medicine ,Humans ,In patient ,Prospective Studies ,Vitamin D ,Prospective cohort study ,030109 nutrition & dietetics ,Nutrition and Dietetics ,Bladder cancer ,business.industry ,Prognosis ,Vitamin D Deficiency ,medicine.disease ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,Quality of Life ,business - Abstract
This study aimed to investigate whether plasma 25-hydroxyvitamin D (25-OHD) at diagnosis predicts poor outcomes in patients with urothelial bladder cancer. A total of 177 patients with non-muscle-invasive bladder cancer (NMIBC) were prospectively followed up over a period extending beyond 6 years. Data on poor outcomes (ie., recurrence, progression, and mortality) were collected. Plasma 25-OHD was measured by immunoassay. Cutoff-Finder web application was used to determine the best 25-OHD cutoff point to predict a specific poor outcome. Cox-hazard models were applied to test how plasma 25-OHD affect patients outcome while adjusting for potential confounding factors. During the follow-up period, tumor recurrence and progression occurred in 40.7% and 14.1% of patients, respectively and 11.3% of patients died. Baseline 25-OHD was lower in patients who experienced poor outcome (12.2 ± 7.44
- Published
- 2020
- Full Text
- View/download PDF